

August 10, 2026

Izotropic Grants RSUs to Consultants

VANCOUVER, British Columbia, and CASABLANCA, Morocco, August 10, 2026, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing [IzoView](#), a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that, it has granted 750,000 Restricted Share Units ("**RSUs**") to various Consultants to support financing and overall business development initiatives, including the establishment of a global manufacturing facility in Morocco and assistance with regulatory approval processes and business launch plans across Africa, the GCC, India and Southeast Asia.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related

to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer

Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1

Email: bthast@izocorp.com

General and Corporate Inquiries

Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3

Email: info@izocorp.com

Izotropic Africa

Email: IZAF@izocorp.com